Journal of AdvancedMedical and Dental Sciences Research

Both concomitant boost radiotherapy and hyper fractionation radiotherapy have been revealed to recover outcomes for patients with head and neck carcinomas. However, both individual approaches moreover increase acute toxicity, and it is doubtful whether anyone can be safely combined.The aim of our study was to find out whether there is any advantage of concomitant boost radiation therapy in controlling head and neck malignancies. The cases were selected from the patients registered at JKCL, LLR and Association hospitals of the G.S.V.M. Medical College, Kanpur. All eligible patients were randomized into two arms as one was conventional group specifying total does of 65 Gy was delivered in 61/2 week with five fractions per week and 200 cGy per day and another was study group specifying Concomitant boost type hyper fractionation in radiotherapy. Total dose of 65 Gy was delivered in weeks (5 days in a week).Grading of response for measurable lesion were done according to guidelines by WHO. For acute radiation, the toxicity grading, system developed by RTOG &EORTC has been used. The chi square test of significance will be used for Statistical analysis. Malignancies of larynx were successfully controlled by concomitant boost radiotherapy, though the result are not statistically significant because of small number of cases, justifies its use as a better treatment increase in complications. As far as the acute RT reactions are concerned can be controlled using of oral glutamines and amifostine during radiotherapy as Documented.